{"id":25465,"date":"2025-04-16T09:33:09","date_gmt":"2025-04-16T07:33:09","guid":{"rendered":"https:\/\/www.izb-online.de\/aatec-medical-erhaelt-4-millionen-euro-fuer-klinische-studien-zu-atemwegstherapien\/"},"modified":"2025-04-16T10:10:43","modified_gmt":"2025-04-16T08:10:43","slug":"aatec-medical-raises-eur-4-million-for-respiratory-drug-trials","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/aatec-medical-raises-eur-4-million-for-respiratory-drug-trials\/","title":{"rendered":"SPRIND & Family Office funding accelerates preparations of AATec Medical’s ATL-105 towards clinical trials for non-CF bronchiectasis by 2026"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text css=”” el_class=”gco-magazine–title”]<\/p>\n

SPRIND & Family Office funding accelerates preparations of AATec Medical’s ATL-105 towards clinical trials for non-CF bronchiectasis by 2026<\/h1>\n

[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-lead”]IZB-based Biotech Startup AATec Medical Secures EUR 4 Million to Advance Novel Respiratory Therapy ATL-105.[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine–post-date”]April, 2025[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” el_id=”corona-ausblenden”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”6283″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]The Lungs[\/vc_column_text][vc_single_image image=”6285″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Stephen S. Yoder<\/strong>, CEO, Pieris Pharmaceuticals Inc.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”25452″ img_size=”full” css=””][vc_column_text css=”” el_class=”gco-magazine-copyright” el_id=”corona-ausblenden”]\u00a9 IZB[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-picture-discription”]IZB-based Biotech Startup AATec Medical Secures EUR 4 Million to Advance Novel Respiratory Therapy ATL-105.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text css=””]<\/p>\n

\u201cWe believe that ATL-105 has the potential to offer a meaningful therapeutic advance for millions of patients worldwide.\u201d<\/h6>\n

Dr. R\u00fcdiger Jankowsky, co-founder and CEO of AATec<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text css=””]AATec Medical GmbH (AATec),\u00a0<\/strong>an IZB-based biotech startup developing a multi-product platform for the treatment of respiratory diseases based on recombinant alpha-1 antitrypsin (AAT), has secured EUR 4 million in a pre-series A financing from Germany\u2019s Federal Agency for Disruptive Innovation (SPRIND) and high-net worth individuals investors, industry experts and single family offices.<\/p>\n

The proceeds will be used to advance the development of ATL-105, AATec\u2019s lead drug candidate in chronic respiratory inflammation and infectious respiratory diseases. ATL-105 will initially be developed for the treatment of non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory respiratory disease without any causative therapies. Current NCFB treatment is limited to symptomatic therapy including antibiotics, macrolides, and physical therapy. The funding will support IND-enabling activities and position ATL-105 for entry into clinical trials by 2026.<\/p>\n

Dr. R\u00fcdiger Jankowsky, co-founder and CEO of AATec, commented: \u201cThis funding is a crucial step toward preparing ATL-105 for clinical development. Non-CF bronchiectasis significantly impacts patients\u2019 quality of life, and current treatment options are limited. We believe that ATL-105 has the potential to offer a meaningful therapeutic advance for millions of patients worldwide. In Western countries alone, more than 3 million patients suffer from NCFB. Thanks to our novel protein inhalation approach, ATL-105 is delivered directly to the lungs, maximizing therapeutic effectiveness at the primary site of inflammation and minimizing systemic side effects. The support from SPRIND validates our innovative approach and highlights the transformative potential of our technology.\u201d<\/p>\n

Sigrid Koeth, Innovation Manager at SPRIND, added: \u201cAt SPRIND, we\u2019re looking for ideas that can fundamentally change things for the better. We believe that AATec\u2019s approach using recombinant alpha-1 antitrypsin has great potential in a wide range of respiratory diseases and infections. Innovations like this can be key in protecting public health and strengthening the resilience of our healthcare systems.\u201d<\/p>\n

AATec Medical\u2019s lead product candidate, ATL-105, is based on a novel recombinant alpha\u20111 antitrypsin (AAT), a human serine protease inhibitor with broad anti-inflammatory, immunomodulatory and anti-infective properties. Robust preclinical proof-of-principle data demonstrate ATL-105\u2019s excellent safety profile and broad therapeutic potential by effectively targeting key pathological processes in inflammatory lung diseases.<\/p>\n

About AATec
\n<\/strong>AATec Medical GmbH is a biotechnology company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-of-concept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit\u00a0www.aatec-medical.com<\/a>\u00a0and follow us on\u00a0LinkedIn<\/a>.<\/p>\n

About SPRIND
\n<\/strong>The Federal Agency for Breakthrough Innovation SPRIND was founded in 2019 and is based in Leipzig. The sole shareholder is the Federal Republic of Germany, represented by the Federal Ministry of Education and Research (BMBF) and the Federal Ministry for Economic Affairs and Climate Action (BMWK). SPRIND closes a gap in the German innovation landscape: It finds new, groundbreaking technologies for the major challenges of our time and at the same time ensures that the added value of the resulting companies and industries remains in Germany and Europe. SPRIND is financed by funds from the federal budget. SPRIND is headed by Rafael Laguna de la Vera and Berit Dannenberg.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n